The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Baricitinib restrains the immune dysregulation in patients with severe COVID-19
Open accessPublished version of a preprint
Abstract
BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT signaling pathways, which can be disabled by small molecules.METHODSWe treated a group of patients (n = 20) with baricitinib according to an off-label use of the drug. The study was designed as an observational, longitudinal trial and approved by the local ethics committee. The patients were treated with 4 mg baricitinib twice daily for 2 days, followed by 4 mg per day for the remaining 7 days. Changes in the immune phenotype and expression of phosphorylated STAT3 (p-STAT3) in blood cells were evaluated and correlated with serum-derived cytokine levels and antibodies against severe acute respiratory syndrome-coronavirus 2 (anti-SARS-CoV-2). In a single treated patient, we also evaluated the alteration of myeloid cell functional activity.RESULTSWe provide evidence that patients treated with baricitinib had a marked reduction in serum levels of IL-6, IL-1β, and TNF-α, a rapid recovery of circulating T and B cell frequencies, and increased antibody production against the SARS-CoV-2 spike protein, all of which were clinically associated with a reduction in the need for oxygen therapy and a progressive increase in the P/F (PaO2, oxygen partial pressure/FiO2, fraction of inspired oxygen) ratio.CONCLUSIONThese data suggest that baricitinib prevented the progression to a severe, extreme form of the viral disease by modulating the patients' immune landscape and that these changes were associated with a safer, more favorable clinical outcome for patients with COVID-19 pneumonia.TRIAL REGISTRATIONClinicalTrials.gov NCT04438629.FUNDINGThis work was supported by the Fondazione Cariverona (ENACT Project) and the Fondazione TIM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Baricitinib, an inhibitor of JAK1 and JAK2, is reported to prevent COVID-19 severity followed by lowering IL-6 and TNFα levels (369).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [369]
Experimental — accuracy not yet measuredIn the citing paper
“In early clinical trials, the use of the JAK inhibitor baricitinib showed a reduction in serum levels of IL-6, IL-1β, and TNF (Bronte et al., 2020)”
From COVID-19 and the human innate immune system (2021) · cites this paper as Bronte et al., 2020
In the citing paper
“Further support comes from positive anecdotal reports of targeted antagonists against interleukin-1, granulocyte–macrophage colony-stimulating factor, and JAK1 and JAK2 in patients with Covid-19.102-105”
From Cytokine storm (2020) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Thevarajan, I., Nguyen, T. H. O., Koutsakos, M., Druce, J. D., Caly, L., van de Sandt, C. E., Jia, X., Nicholson, S. R., Catton, M. C., Cowie, B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0819-2 · Cited by 993
Cited by
Sorted by citations
Items 101–200 of 280
Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis
Musiu, C., Caligola, S., Fiore, A., Lamolinara, A., Frusteri, C., Pizzo, F. D. D., Sanctis, F. D., Canè, S., Adamo, A., Hofer, F., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00866-0 · Cited by 23
Self-citationTherapeutic potential of induced iron depletion using iron chelators in Covid-19
Naseef, P. P., Elayadeth‐Meethal, M., Salim, K. T. M., Anjana, A., Muhas, C., Vajid, K. A., & Kuruniyan, M. S. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.11.061 · Cited by 24
Therapeutic role of immunomodulators during the COVID-19 pandemic– a narrative review
Alhajeri, H., Baron, F., Abutiban, F., Mutairi, M. A., Ali, Y., Al-Awadhi, A. M., Albasri, A., Aldei, A., Alenizi, A., Alhadhood, N., et al. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2033563 · Cited by 25
Patel, N. M., Collotta, D., Aimaretti, E., Alves, G. F., Kröller, S., Coldewey, S. M., Collino, M., & Thiemermann, C. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005571 · Cited by 24
Immune interventions in COVID-19: a matter of time?
Plaçais, L., Richier, Q., Noël, N., Lacombe, K., Mariette, X., & Hermine, O. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00464-w · Cited by 22
Zhang, W., Qin, C., Fei, Y., Shen, M. Y., Zhou, Y., Zhang, Y., Zeng, X., & Zhang, S. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109022 · Cited by 23
Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection
Bauer, W., Weber, M., Diehl-Wiesenecker, E. C., Galtung, N., Prpic, M., Somasundaram, R., Tauber, R., Schwenk, J. M., Micke, P., & Kappert, K. (2021) · Viruses · doi:10.3390/v13122456 · Cited by 22
Ely, E. W., Ramanan, A. V., Kartman, C. E., de Bono, S., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Saraiva, J. F. K., Chakladar, S., & Marconi, V. C. (2021) · medRxiv · doi:10.1101/2021.10.11.21263897 · Cited by 22
Lee, M., Chen, Y., Tsai-Wu, J.-J., Hsu, Y., & Lin, B. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119752 · Cited by 21
Chilosi, M., Doglioni, C., Ravaglia, C., Martignoni, G., Salvagno, G. L., Pizzolo, G., Bronte, V., & Poletti, V. E. (2022) · Biomedicines · doi:10.3390/biomedicines10061332 · Cited by 22
Self-citationImmune response to COVID-19 infection: a double-edged sword
Saad, N. M., & Moussa, S. (2021) · Immunological Medicine · doi:10.1080/25785826.2020.1870305 · Cited by 21
Mabrey, F. L., Nian, H., Yu, C., Barnes, E. M., Malhotra, U., Mikacenic, C. R., Goldstein, J., O’Mahony, D. S., Garcia‐Diaz, J., Finn, P. W., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104667 · Cited by 22
Barilli, A., Visigalli, R., Ferrari, F., Luciani, G. R., Soli, M., Dall’Asta, V., & Rotoli, B. M. (2022) · Biomedicines · doi:10.3390/biomedicines10092324 · Cited by 21
Bobčáková, A., Barnova, M., Vyšehradský, R., Petriskova, J., Kocan, I., Diamant, Z., & Jeseňák, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861666 · Cited by 19
COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients
Szekanecz, Z., Balog, A., Constantin, T., Czirják, L., Géher, P., Kovács, L., Kumánovics, G., Nagy, G., Rákóczi, É., Szamosi, S., et al. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.10 · Cited by 19
COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us?
Gallo, C. G., Fiorino, S., Posabella, G., Antonacci, D., Tropeano, A., Pausini, E., Pausini, C., Guarniero, T., Hong, W., Giampieri, E., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155628 · Cited by 17
Recent clinical findings on the role of kinase inhibitors in COVID-19 management
Malekinejad, Z., Baghbanzadeh, A., Nakhlband, A., Baradaran, B., Jafari, S., Bagheri, Y., Raei, F., Montazersaheb, S., & Farahzadi, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120809 · Cited by 20
Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID‐19
Bolla, A. M., Loretelli, C., Montefusco, L. B., Finzi, G., Abdi, R., Nasr, M. B., Lunati, M. E., Pastore, I., Bonventre, J. V., Nebuloni, M., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3565 · Cited by 16
Ciccocioppo, R., Gibellini, D., Astori, G., Bernardi, M., Bozza, A., Chieregato, K., Elice, F., Ugel, S., Caligola, S., Sanctis, F. D., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02376-9 · Cited by 17
Self-citationKumar, A., Sharma, A., Tirpude, N. V., Sharma, S., Padwad, Y. S., & Kumar, S. (2022) · Inflammopharmacology · doi:10.1007/s10787-021-00903-x · Cited by 18
Liu, J. M., & Chi, J. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702211068840 · Cited by 18
Fard, S. N., Petruccioli, E., Farroni, C., Petrone, L., Vanini, V., Cuzzi, G., Salmi, A., Altera, A. M. G., Navarra, A., Alonzi, T., et al. (2022) · Frontiers in Immunology · doi:10.2139/ssrn.4128851 · Cited by 17
Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance
Scaramuzzo, G., Nucera, F., Asmundo, A., Messina, R., Mari, M., Montanaro, F., Johansen, M. D., Monaco, F. L., Fadda, G., Tuccari, G., et al. (2023) · Journal of Inflammation · doi:10.1186/s12950-023-00333-2 · Cited by 17
Fritch, E. J., Mordant, A. L., Gilbert, T. S. K., Wells, C. I., Yang, X., Barker, N. K., Madden, E. A., Dinnon, K. H., Hou, Y. J., Tse, L. V., et al. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00182 · Cited by 17
Masiá, M., Padilla, S., García, J. A., García‐Abellán, J., Navarro‐Ruiz, A., Guillén, L., Telenti, G., Mascarell, P., Botella, Á., & Gutiérrez, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.749657 · Cited by 17
Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm
Niedźwiedzka‐Rystwej, P., Majchrzak, A., Kurkowska, S., Małkowska, P., Sierawska, O., Hrynkiewicz, R., & Parczewski, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094545 · Cited by 19
Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
Thoms, B. L., Gosselin, J., Libman, B. S., Littenberg, B., & Budd, R. C. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01121-4 · Cited by 15
Dysregulation of the leukocyte signaling landscape during acute COVID-19
Turnbull, I. R., Fuchs, A. G., Remy, K. E., Kelly, M. P., Frazier, E. P., Ghosh, S., Chang, S.-W., Mazer, M. B., Hess, A., Leonard, J. M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264979 · Cited by 13
The Immunopathobiology of SARS-CoV-2 Infection
Patel, M., Shahjin, F., Cohen, J. D., Hasan, M., Machhi, J., Chugh, H., Singh, S., Das, S., Kulkarni, T. A., Herskovitz, J., et al. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab035 · Cited by 15
Discovery of new drug indications for COVID-19: A drug repurposing approach
Kumari, P., Pradhan, B., Koromina, M., Patrinos, G. P., & Steen, K. V. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267095 · Cited by 13
Weapons and Strategies against COVID-19: A Perspective
Mishra, R., Chaudhary, K., & Mishra, I. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230525161432 · Cited by 13
Contemporary narrative review of treatment options for COVID ‐19
Shang, L., Lye, D. C., & Cao, B. (2021) · Respirology · doi:10.1111/resp.14106 · Cited by 11
Nasonov, E. L., & Korotaeva, T. V. (2022) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2022-131-148 · Cited by 12
Manoharan, S., & Ying, L. Y. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.106986 · Cited by 12
Musters, A. H., Broderick, C., Prieto‐Merino, D., Chiricozzi, A., Damiani, G. B., Peris, K., Dhar, S., De, A., Freeman, E. E., Arents, B. W. M., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18613 · Cited by 12
Adamo, A., Frusteri, C., Pilotto, S., Caligola, S., Belluomini, L., Poffe, O., Giacobazzi, L., Dusi, S., Musiu, C., Hu, Y., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2253644 · Cited by 12
Self-citationPersistent immune dysregulation and metabolic alterations following SARS-CoV-2 infectionPreprint
Lage, S. L., Bricker, K. M., Rocco, J. M., Rupert, A. W., Donovan, F. X., Abramzon, Y. A., Chandrasekharappa, S. C., McNinch, C. M., Cook, L., Amaral, E. P., et al. (2025) · medRxiv · doi:10.1101/2025.04.16.25325949 · Cited by 12
Antivirális és gyulladásellenes kezelési lehetőségek COVID–19-ben
Szekanecz, Z., Bogos, K., Constantin, T., Fülesdi, B., Müller, V., Rákóczi, É., Várkonyi, I. Z., & Valyi-Nagy, I. T. (2021) · Orvosi Hetilap · doi:10.1556/650.2021.32230 · Cited by 11
Modalities and Mechanisms of Treatment for Coronavirus Disease 2019
Zuo, Z., Wu, T., Pan, L., Zuo, C., Hu, Y., Luo, X., Jiang, L., Xia, Z., Xiao, X., Liu, J., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.583914 · Cited by 14
Infection‐induced inflammation from specific inborn errors of immunity to COVID‐19
Ku, C., Chen, I., & Lai, M. (2021) · FEBS Journal · doi:10.1111/febs.15961 · Cited by 11
Tekantapeh, S. T., Ghojazadeh, M., Ghamari, A. A., Mohammadi, A., & Soleimanpour, H. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2114899 · Cited by 11
Anton, D. B., Pedreira, J. G. B., Zvirtes, M. L., Laufer, S., Ducati, R. G., Goettert, M. I., & Timmers, L. F. S. M. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00324 · Cited by 11
Luciani, G. R., Barilli, A., Visigalli, R., Sala, R., Dall’Asta, V., & Rotoli, B. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063463 · Cited by 12
Wong, C. K. H., Lau, K. T. K., Au, I. C. H., Xiong, X., Chung, M. S. H., Leung, B. Y. C., Lau, E. H. Y., & Cowling, B. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.866441 · Cited by 11
Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?
Esposito, R., Mirra, D., Sportiello, L., Spaziano, G., & D’Agostino, B. (2022) · Biomedicines · doi:10.3390/biomedicines10112815 · Cited by 12
Essa, R. A., Ahmed, S. K., Bapir, D. H., Abubakr, C. P., Rasul, S. A., Khdir, A., & Wsu, Z. H. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102814 · Cited by 12
Sun, J., Wang, S., Ma, X., Wei, Q., Peng, Y., Bai, Y., Miao, G., Meng, C., & Liu, P. (2023) · European journal of medical research · doi:10.1186/s40001-023-01403-0 · Cited by 10
Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review
Dupuis, D., Fritz, K., Ike, E., Arogundade, O., Adewara, E. O., Monday, E. O., & Ayinde, B. O. (2022) · Cureus · doi:10.7759/cureus.28680 · Cited by 10
A Brief Study on Drug Repurposing: New Way of Boosting Drug Discovery
Mazumder, R., KAUSHIK, K. K., Debnath, A., & Patel, M. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220901170016 · Cited by 10
Anti-MDA5+ dermatomyositis following SARS-COV-2 infections: a systematic review
Lattarulo, S., Centrone, F., & Chironna, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565803 · Cited by 9
Tziolos, N., Karofylakis, E., Grigoropoulos, I., Kazakou, P., Koullias, E., Savva, A., Kranidioti, H., Πελεκάνου, Α., Boulouta, A., Pirounaki, M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab588 · Cited by 9
Use of baricitinib in treatment of COVID‐19: a systematic review
Sampath, A., Banerjee, A., Atal, S., & Jhaj, R. (2023) · Medicinal Research Reviews · doi:10.1002/med.21951 · Cited by 9
Farcy, D. A., Dalley, M. T., Miro, G., Swalley, P., Sherman, D., Nash, J., Jodoin, K., Cubeddu, L. X., Zitek, T., & Goldszer, R. C. (2021) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.07.025 · Cited by 9
Efficacy of COVID-19 treatments among geriatric patients: a systematic review
Senderovich, H., Vinoraj, D., Stever, M., & Waicus, S. (2022) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361221095666 · Cited by 9
Walz, L., Cohen, A. J., Rebaza, A. P., Vanchieri, J., Slade, M. D., Cruz, C. S. D., & Sharma, L. (2020) · Research Square · doi:10.21203/rs.3.rs-64782/v1 · Cited by 10
Multi-omics analysis uncovered systemic lupus erythematosus and COVID-19 crosstalk
Nian, Z., Mao, Y., Xu, Z., Deng, M., Xu, Y., Xu, H., Chen, R., Xu, Y., Huang, N., Mao, F., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00851-6 · Cited by 8
Li, J., Mao, N., Wang, Y., Deng, S., & Chen, K. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.011 · Cited by 9
Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment
Oba, S., Hosoya, T., Iwai, H., & Yasuda, S. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2570902 · Cited by 11
Li, X., Zhang, Y., He, L., Si, J., Qiu, S., He, Y., Wei, J., Wang, Z., Xie, L., Li, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66369 · Cited by 8
Scanlan, A., Zhang, Z., Koneru, R., Reece, M. D., Gavegnano, C., Anderson, A. M. L., & Tyor, W. R. (2022) · Microorganisms · doi:10.3390/microorganisms10112244 · Cited by 8
Jiao, G., Fan, X., Wang, Y., Weng, N., Ouyang, L., Wang, H., Pan, S., Huang, D., Han, J. H., Zhang, F., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c04589 · Cited by 8
COVID-19 and Its Impact on Common Diseases in the Allergy Clinics
Kocatürk, E., Abrams, E. M., Maurer, M., Mitri, J., Oppenheimer, J. J., Vestergaard, C., & Zein, J. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.08.038 · Cited by 8
Cytokine-Induced iNOS in A549 Alveolar Epithelial Cells: A Potential Role in COVID-19 Lung Pathology
Barilli, A., Luciani, G. R., Visigalli, R., Sala, R., Soli, M., Dall’Asta, V., & Rotoli, B. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102699 · Cited by 9
The Binary Model of Chronic Diseases Applied to COVID-19
Elkoshi, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716084 · Cited by 8
Crammond, P., Hastak, P., Delaney, A. P., & Sasson, S. C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1761361 · Cited by 8
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
Bosch‐Barrera, J., Roqué, A., Teixidor, E., Carmona-Garcia, M. C., Arbusà, A., Brunet, J., Martı́n-Castillo, B., Cuyàs, E., Verdura, S., & Menéndez, J. A. (2021) · Pharmaceuticals · doi:10.3390/ph15010019 · Cited by 7
Systematic Review: JAK-STAT Regulation and Its Impact on Inflammation Response in ARDS from COVID-19
Rodriguez, I., & Carnevale, K. J. F. (2024) · Immuno · doi:10.3390/immuno4020010 · Cited by 7
JAK Inhibitors in Cytokine Storm Syndromes
Keenan, C., Albeituni, S., Nichols, K. E., & Hines, M. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_39 · Cited by 7
Chen, J., & Ostermann, M. (2022) · Critical Care Clinics · doi:10.1016/j.ccc.2022.02.002 · Cited by 10
ARNANDA, N., & Ramatillah, D. L. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022.v14s2.44739 · Cited by 7
Upadhyay, A. A., Hoang, T., Pino, M., Boddapati, A. K., Viox, E. G., Lee, M., Corry, J., Strongin, Z., Cowan, D. A., Beagle, E. N., et al. (2021) · bioRxiv · doi:10.1101/2021.10.05.463212 · Cited by 7
Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy
Žák, J., & Teijaro, J. R. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01266-6 · Cited by 6
Paules, C. I., Wang, J., Tomashek, K. M., Bonnett, T., Singh, K., Marconi, V. C., Davey, R. T., Lye, D. C., Dodd, L. E., Yang, O. O., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2593 · Cited by 6
Sinaei, R., Pezeshki, S., Asadipour, A., Shiari, R., Sinaei, R., & Sinaei, A. (2021) · Pharmaceutical Sciences · doi:10.34172/ps.2021.40 · Cited by 6
Banerjee, A., Goswami, R. P., & Chatterjee, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-82139-x · Cited by 6
Atemnkeng, F. N., Alataby, H., Demirjian, J., Kenne, F. M., & Nfonoyim, J. M. (2021) · Journal of Medical Cases · doi:10.14740/jmc3629 · Cited by 6
Yasuda, Y., Hirayama, Y., Uemasu, K., Arasawa, S., Iwashima, D., & Takahashi, K. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100903 · Cited by 6
Barilli, A., Visigalli, R., Ferrari, F., Luciani, G. R., Soli, M., Dall’Asta, V., & Rotoli, B. M. (2022) · Biomedicines · doi:10.3390/biomedicines10123085 · Cited by 6
Caring for patients in a new pandemic: the necessity and challenges of observational research
Thomas, D. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci143292 · Cited by 6
Silva‐Filho, J. L., Herder, V., Gibbins, M. P., dos Reis, M. F., de Melo, G. C., Haley, M., Judice, C. C., Val, F., Borba, M. G. S., Tavella, T. A., et al. (2023) · medRxiv · doi:10.1101/2023.09.08.23295024 · Cited by 6
Kwon, G., Park, Y., Kang, K., Park‐Min, K., & Kang, K. (2025) · iScience · doi:10.1016/j.isci.2025.112502 · Cited by 5
STATs, promising targets for the treatment of autoimmune and inflammatory diseases
He, X., Liu, P., Luo, Y., Fu, X.-Y., & Yang, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116783 · Cited by 5
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19
Seethamraju, H., Yang, O. O., Loftus, R., Ogbuagu, O. E., Sammartino, D. E., Mansour, A. E., Sacha, J. B., Ojha, S., Hansen, S. G., Arman, A. C., et al. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.08.019 · Cited by 5
Role of baricitinib in COVID-19 patients: A systematic review and meta-analysis
Thakur, M., Babu, A., Khatik, G. L., Datusalia, A. K., Khatri, R., & Kumar, A. (2023) · World Journal of Meta-Analysis · doi:10.13105/wjma.v11.i4.125 · Cited by 5
COVID‑19 in China: From epidemiology to treatment (Review)
Chen, H., Wu, S., & Zhang, X. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9353 · Cited by 6
The role of immunomodulatory medications in the treatment of COVID-19
Sattui, S. E., Crow, M. K., & Navarro-Millán, I. Y. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000817 · Cited by 5
Can rheumatologists stop causing demyelinating disease?
Baker, D., Hadjicharalambous, C., Gnanapavan, S., & Giovannoni, G. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103057 · Cited by 5
Andaluz‐Ojeda, D., Vidal, P., Sanz, Á. A., Suberviola, B., Carbajo, L. D. R., Martín, L. N., Silva, E. P., Olmo, J. N.-D., Barberán, J., & Cusácovich, I. (2022) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v11.i4.269 · Cited by 6
Host-Based Treatments for Severe COVID-19
Mondini, L., Salton, F., Trotta, L., Bozzi, C., Pozzan, R., Barbieri, M., Tavano, S., Lerda, S., Hughes, M., Confalonieri, M., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040203 · Cited by 4
Severe COVID-19: Drugs and Clinical Trials
Ceja-Gálvez, H. R., Renteria-Flores, F. I., Nicoletti, F., Hernández‐Bello, J., Ojeda, G. M., & Muñóz-Valle, J. F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082893 · Cited by 5
Kinoshita, H., Kurashige, T., Fukuda, T., Morita, M., Maeda, S., Kanegawa, M., Sumimoto, Y., Masada, K., Shimonaga, T., & Sugino, H. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16512 · Cited by 4
Herrero, C. G., & Thallmair, S. (2024) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.4c02875 · Cited by 4
A hitchhiker's guide through the COVID-19 galaxy
Felsenstein, S., & Reiff, A. O. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108849 · Cited by 4
Impact of cytidine diphosphocholine on oxygenation in client-owned dogs with aspiration pneumonia
Young, A. A., Rosas, L. E., Cooper, E. S., Yaxley, P. E., & Davis, I. C. (2022) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16434 · Cited by 4
Kai, Y., Matsuda, M., Suzuki, K., Kasamatsu, T., Kajita, A., Uno, K., & Muro, S. (2022) · Cureus · doi:10.7759/cureus.23411 · Cited by 4
Treating COVID-19: Targeting the Host Response, Not the Virus
Fedson, D. S. (2023) · Life · doi:10.3390/life13030712 · Cited by 4
Computational insight of repurpose drug for treatment of COVID-19: a CDFT approach
Ranjan, P., & Chakraborty, T. (2023) · Theoretical Chemistry Accounts · doi:10.1007/s00214-023-03082-w · Cited by 4
COVID‐19 and rheumatology: Reflecting on the first wave and preparing for the second wave
Fardanesh, A., Byravan, S., Moorthy, A., & Tahir, H. (2021) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14062 · Cited by 4
c-FLIP as a master regulator of immune homeostasis and disease mechanisms
Urbini, E., Adamo, A., Hu, Y., Giacobazzi, L., Dusi, S., Sanctis, F. D., Carbone, C., Gibellini, D., Pilotto, S., Corbo, V., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08771-5 · Cited by 6
Self-citationLiu, H., Chen, J., Shao, W., Su, Y., & Ding, S. (2023) · Clinical Epidemiology · doi:10.2147/clep.s422386 · Cited by 3
Metadata
- Authors
- Bronte, V., Ugel, S., Tinazzi, E., Vella, A., De Sanctis, F., Canè, S., Batani, V., Trovato, R., Fiore, A., Petrova, V., Hofer, F., Barouni, R. M., Musiu, C., Caligola, S., Pinton, L., Torroni, L., Polati, E., Donadello, K., Friso, S., Pizzolo, F., Iezzi, M., Facciotti, F., Pelicci, P. G., Righetti, D., Bazzoni, P., Rampudda, M., Comel, A., Mosaner, W., Lunardi, C., & Olivieri, O.
- Affiliations
- University of Verona (IT)
- European Institute of Oncology (IT)
- Ospedale P. Pederzoli – Casa di Cura Privata S.p.a. (IT)
- Corresponding author
- Bronte, Vincenzo
- ORCID
- Bronte, Vincenzo
- Ugel, Stefano
- Tinazzi, Elisa
- Vella, Antonio
- Canè, Stefania
- Batani, Veronica
- Trovato, Rosalinda
- Fiore, Alessandra
- Petrova, Varvara
- Hofer, Francesca
- Barouni, Roza Maria
- Musiu, Chiara
- Caligola, Simone
- Pinton, Laura
- Torroni, Lorena
- Polati, Enrico
- Donadello, Katia
- Friso, Simonetta
- Pizzolo, Francesca
- Iezzi, Manuela
- Facciotti, Federica
- Pelicci, Pier Giuseppe
- Lunardi, Claudio
- Olivieri, Oliviero
- Venue
- Journal of Clinical Investigation
- Published
- 2020-11-03
- Volume
- 130
- Issue
- 12
- Pages
- 6409-6416
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC8016181
- OpenAlex
- W3037867966
- Cited by
- 281
- References
- 23
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 23 · 2023: 39 · 2022: 72 · 2021: 89 · 2020: 23
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Fondazione Cariverona Italy (ENACT)
- Fondazione TIM Italy (IMMUNOVID)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- baricitinib, COVID-19 pandemic, SARS-CoV-2, JAK/STAT signaling, STAT3 phosphorylation, cytokine storm, interleukin-6, IL-1β, TNF-α, lymphopenia, T cell reconstitution, B cell recovery, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Aged, Aged, 80 and over, Azetidines, B-Lymphocytes, Female, Humans, Longitudinal Studies, Male, Middle Aged, Purines, Pyrazoles, Severity of Illness Index, Sulfonamides, T-Lymphocytes, Cytokines, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
